Genomic Health

WeightWatchers Appoints New Executive Leaders

Retrieved on: 
木曜日, 4月 11, 2024
LEGO, General counsel, PepsiCo, Genomic Health, Columbidae, Oracle, Privacy, Digital, IPO, SVP, Senior, Science, Acquisition, WW, Hyperion, Marketing, Stitch Fix, Associate, WW International, Biotechnology, Teladoc Health, Yahoo!, Latham & Watkins, Management

Debra Benovitz joined WeightWatchers in 2014 as SVP of Global Consumer Insights to guide the WeightWatchers user experience across product and marketing with data-backed insights.

Key Points: 
  • Debra Benovitz joined WeightWatchers in 2014 as SVP of Global Consumer Insights to guide the WeightWatchers user experience across product and marketing with data-backed insights.
  • She joined the Company’s leadership in 2015, and her role has become even more essential to guarantee all cross-functional touchpoints resonate with WeightWatchers members.
  • Her recent promotion to Chief Insights Officer expands her role to oversee all science and clinical research, including WeightWatchers #1 doctor recommended Points Program.
  • With more than 30 years of consumer insights experience, Debra has made significant contributions to WeightWatchers, delivering strategic consumer insights that drive business growth.

23andMe Launches New Genetic Reports on Common Forms of Cancer

Retrieved on: 
水曜日, 3月 6, 2024
African Americans, SAN, Breast cancer, American Cancer Society, Cancer, Breast, 23andMe, Health, Genetics, Genomic Health, Database, PRS, Genetic, Patient, Black, Disease, Machine learning, Colorectal cancer, Premium, Research, Prostate cancer, Dietary supplement

The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.

Key Points: 
  • The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.
  • Availability of the breast cancer and prostate cancer PRS reports is based on self-reported birth sex.
  • The PRS models on which the new 23andMe reports are based were developed using the 23andMe database, and further validated using an external database.
  • To learn more about the new 23andMe PRS reports on cancer, and becoming a 23andMe+ Premium member, visit https://www.23andme.com/membership/ .

Know Your Lemons® Foundation acquires Dr. Susan Love Foundation for Breast Cancer Research ImPatient Science® Video Series for Breast Cancer Patients

Retrieved on: 
金曜日, 12月 22, 2023
Literacy, Partnership, Fitness, Fear, Breast cancer, Caregiver, Friends, Physical fitness, Disease, MBA, MD, Health, Novartis, Genomic Health, Impatient, Confusion, Volunteering, Merck, FAQ, Patient, Risk, Diagnosis, Knowledge, Birth control

Dr. Susan Love, MD, MBA developed the series in 2015 as a part of her path breaking work as a breast cancer surgeon, researcher and educator.

Key Points: 
  • Dr. Susan Love, MD, MBA developed the series in 2015 as a part of her path breaking work as a breast cancer surgeon, researcher and educator.
  • "Our core mission is extended and deepened by this partnership with the Dr. Susan Love Foundation," said Corrine Ellsworth-Beaumont, CEO & Founder of Know Your Lemons Foundation.
  • Dr. Susan Love understood that patients facing a breast cancer diagnosis were often overwhelmed with fear, confusion and, very simply, a lack of explanations about what breast cancer was and how it might affect their lives.
  • The ImPatient Science educational series was underwritten by these generous partners of the Dr. Susan Love Foundation: Avon Breast Cancer Crusade, Celgene, Genentech, Genomic Health, Merck, Novartis, and Pfizer Oncology.

Adela Appoints Precision Medicine Veteran Lisa Alderson as CEO

Retrieved on: 
木曜日, 12月 14, 2023
Health, Sinai Health System, Princess Margaret Cancer Centre, University Health Network, Medicine, MRD, Adela de la Torre, Genomic Health, Growth, Biology, Management

FOSTER CITY, Calif., Dec. 14, 2023 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, today announced the appointment of Lisa Alderson as Chief Executive Officer, following an extensive, nationwide search. Ms. Alderson is uniquely positioned to guide Adela through product scaling and commercialization, based on her prior leadership roles at Genome Medical, Invitae, and Genomic Health.

Key Points: 
  • "We are thrilled to appoint Ms. Alderson to lead Adela through its next phase of growth", said David Scheer, Chairman of Adela's Board of Directors.
  • Serving most recently as interim CEO to Adela, she has already demonstrated her ability to engage and lead this mission-driven organization in delivering results."
  • Ms. Alderson previously co-founded and served as the CEO of Genome Medical, the leading genomic care delivery company enabling broad-based access to genomic medicine.
  • "I'm excited to guide Adela through product development, commercialization and growth with the goal of applying our innovative technology to advance patient care in oncology," said Lisa Alderson, CEO, Adela.

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

Retrieved on: 
火曜日, 11月 7, 2023
Knowledge, FDA, Medical genetics, American College, 23andMe, DPYD, Genetic testing, ACMG, Polygene, Biomarker, Health, Ovarian cancer, Therapy, Life, BRCA1, Reading, Genetics, Citalopram, Liver, Kidney, Research, Prostate cancer, Clinical Pharmacogenetics Implementation Consortium, Pharmacogenomics, Metabolism, Genomic Health, BRCA2, Genome, Heredity, Disease, LDL, CYP2C19, Risk, Asthma, Risk assessment, Cancer, Breast cancer, Saliva, Pancreatic cancer, PGS, Fetus, Gene, SLCO1B1, Anxiety, Breast, American College of Medical Genetics and Genomics, Lijun International Pharmaceutical (Holding) Co. Ltd., Cholesterol, SAN, DNA, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.
  • Members of Total Health will also receive all the reports and features offered in the Company’s existing 23andMe+ Premium Membership .
  • As part of Total Health, members will gain access to all the premium reports and features delivered through 23andMe+ Premium.
  • The 23andMe+ Total Health membership will cost $99 per month, billed in a one-time annual payment of $1,188.

Mdxhealth's New Share Capital Amount and New Number of Shares

Retrieved on: 
金曜日, 10月 20, 2023
Leymus innovatus, Genomics, Disclosure, Acquisition, Genomic Health, American depositary receipt, Oncotype (Denmark), ADS, EUR, USD, Article, Security (finance)

IRVINE, CA, and HERSTAL, BELGIUM – October 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of a capital increase completed on October 20, 2023, the Company's share capital has increased from EUR 163,471,629.58 to EUR 164,302,752.89 and the number of issued and outstanding shares has increased from 270,380,936 to 272,880,936 ordinary shares, through the issuance of a total of 2,500,000 new shares.

Key Points: 
  • IRVINE, CA, and HERSTAL, BELGIUM – October 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of a capital increase completed on October 20, 2023, the Company's share capital has increased from EUR 163,471,629.58 to EUR 164,302,752.89 and the number of issued and outstanding shares has increased from 270,380,936 to 272,880,936 ordinary shares, through the issuance of a total of 2,500,000 new shares.
  • The new shares were issued pursuant to the amendment, announced on August 23, 2023, to the asset purchase agreement for the acquisition by the Company of the Oncotype DX® GPS (Genomic Prostate Score®) test from Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation).
  • In addition to the outstanding shares of the Company:
    a total of 18,560,124 subscription rights of the Company are outstanding, which entitles their holders (assuming all subscription rights are granted and exercised) to subscribe to a total of 18,560,124 new shares with voting rights; and
    under the loan and security agreement entered into by the Company and Innovatus Capital Partners in August 2022, Innovatus has the right to convert, prior to August 2, 2025, up to 15% of the outstanding principal amount of the loans (by means of a contribution in kind of the relevant payables due by the Company under the loans) into American Depositary Shares ("ADSs") of the Company (each representing 10 ordinary shares of the Company) at a conversion price per ADS equal to USD 11.21 (i.e., USD 1.121 per share on the basis of the ratio of 1 ADS per 10 shares).

Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

Retrieved on: 
水曜日, 9月 27, 2023
Oncology, Medical Devices, Health, Health Technology, Research, Science, Genomic Health, University, Brigham and Women's Hospital, Duke University School of Medicine, Cancer, Multimedia, Medicine, Dartmouth College, Dana–Farber Cancer Institute, Reagan-Udall Foundation, Patient, Physician, Mortality, Hospital, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Microbiology, Dana, Nursing, Pharmaceutical industry, Illumina, Biology

Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer.
  • He will report to Marc Stapley, Veracyte’s chief executive officer.
  • View the full release here: https://www.businesswire.com/news/home/20230927846710/en/
    Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Photo: Business Wire)
    “Phil is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley.
  • He most recently served as chief medical officer for Illumina where he built the medical team and led the successful strategy to engage clinical customers.

Mount Sinai Announces New System Chief of Genomic Medicine

Retrieved on: 
火曜日, 9月 26, 2023
Genomic Health, Cleveland Clinic, University, Population health, Genetics, Icahn School of Medicine at Mount Sinai, Public, Yale New Haven Health System, Murray, Brigham and Women's Hospital, University college, Research, Department of Medicine – University of Pamplona, DSM-IV codes, Mount Sinai, Genetic distance, Doctor of Philosophy, Harvard Medical School, Publication, MD, American College of Medical Genetics and Genomics, Patient, Division, Internal medicine, Cancer, James D. Watson Institute of Genome Sciences, Clinical, Diagnosis, Hospital, Medical genetics, American College, Health, Mount Sinai Health System, Penn State University College of Medicine, Vaccine, Pharmaceutical industry, Medical device, Genomics, Medicine

NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai. He will lead its efforts to harness the power of genomic discovery to develop new ways to prevent and treat diseases, including cancers, heart problems, and genetic disorders.

Key Points: 
  • Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai.
  • NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai.
  • Before joining the Mount Sinai Health System, he led cutting-edge efforts to integrate genomic medicine into clinical care delivery at Harvard Medical School, Geisinger Community Medical Center, and Yale New Haven Health System.
  • "With the investment that the Mount Sinai Health System has made in genetics and genomics technology in the clinical and research arenas, we are making an impact upon the care we provide to patients in a significant way," said Monica Kraft, MD, the Murray M. Rosenberg Professor of Medicine and System Chair of the Department of Medicine at Mount Sinai Health System and Icahn Mount Sinai.

Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach

Retrieved on: 
月曜日, 9月 25, 2023
Interim, Sinai Health System, Genomic Health, Princess Margaret Cancer Centre, University Health Network, OrbiMed, Cancer, Adela Investment Company, MRD, Patient, Growth, Labcorp, Management

FOSTER CITY, Calif., Sept. 25, 2023 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a genome-wide methylome approach, announced today the closing of $48 million in financing. In addition, the company announced that Lisa Alderson will join Adela as interim Chief Executive Officer (CEO), succeeding Dr. Scott Bratman. Dr. Bratman will continue to serve as a member of Adela's Board of Directors and as President.

Key Points: 
  • In addition, the company announced that Lisa Alderson will join Adela as interim Chief Executive Officer (CEO), succeeding Dr. Scott Bratman.
  • The proceeds from the financing will be used to advance Adela's technology platform and commercialize Adela's first product for MRD monitoring.
  • Adela's tissue-agnostic MRD monitoring product is based on its genome-wide methylome enrichment platform, which efficiently captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions.
  • The proceeds will also be used to continue development of the company's multi-cancer early detection (MCED) product, based on the same platform.

Mercy BioAnalytics Adds Marketing and Portfolio Management Leadership to Support Diagnostic Test Development and Commercialization

Retrieved on: 
月曜日, 9月 11, 2023
Oncology, Health, Biometrics, Genetics, General Health, Biotechnology, Genomic Health, Project management office, BS, Information technology, California State University, Cancer, MBA, Jonathan Rothberg, Exact sciences, Marketing, Medtronic, Bio-Rad Laboratories, Santa Clara University, ESV, Patient, Commercial, PMO, Biopsy, Management, Chemistry, Mercy

Josh Gralapp has joined Mercy as Vice President for Marketing and Strategic Alliances, while Tim Membrino has joined as Vice President for Program and Portfolio Management.

Key Points: 
  • Josh Gralapp has joined Mercy as Vice President for Marketing and Strategic Alliances, while Tim Membrino has joined as Vice President for Program and Portfolio Management.
  • Previously, he held marketing leadership roles at Exact Sciences and Genomic Health with their urologic oncology diagnostic test portfolios.
  • His depth and breadth of experience in diagnostic test commercialization has been an immediately impactful addition to Mercy’s leadership team.
  • “I’m thrilled to join an executive team that embraces Program and Portfolio Management best practices paired with robust clinical development efforts as we drive Mercy’s test portfolio through the product realization life cycle.”